Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 98-107 , January 2010

Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis

  • William L. Baker

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, CT, United States
    • Hartford Hospital, Hartford, CT, United States
    • ,
  • Ripple Talati

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, CT, United States
    • Hartford Hospital, Hartford, CT, United States
    • ,
  • C. Michael White

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, CT, United States
    • Hartford Hospital, Hartford, CT, United States
    • ,
  • Craig I. Coleman

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, CT, United States
    • Hartford Hospital, Hartford, CT, United States
    • Corresponding Author InformationCorresponding author at: University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102-5037, United States. Tel.: +1 860 545 2096; fax: +1 860 545 2277.

Received 11 August 2009 ,Revised 8 October 2009 ,Accepted 13 October 2009.

References 

  1. Colhoun HM, Betteridge DJ, Hitman GM. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet. 2004;364:658–696
  2. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations. Lancet. 2002;359:1379–1387
  3. Sever PS, Dahlor B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361:1149–1158
  4. Heart Protection Study Collaborative Group. MCR/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet. 2002;360:7–22
  5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007
  6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in Elderly individuals at Risk of Vascular Disease (PROSPER). Lancet. 2002;360:1623–1630
  7. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. for the Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215–3222
  8. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87:1074–1079
  9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  11. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGH, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  13. Dale KM, White CM, Henyan NN, Kluger J, Coleman CI. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med. 2007;120:706–712
  14. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80
  15. Alsheikh-Ali AA, Trinkalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol. 2008;52:1141–1147
  16. Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, et al. Pravastatin in the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–362
  17. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359–1362
  18. Ridker PM, Danielson E, Fonseca FAH, Gonest J, Gotto AM, Kastelein JJP, et al. for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195–2207
  19. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782
  20. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009;204:483–490
  21. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels in insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol. 2008;590:327–332
  22. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PHR, Nestel P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis. 2008;197:732–739
  23. Ooi EMM, Barrett PHR, Chan DC, Nestel PJ, Watts GF. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis. 2008;197:139–146
  24. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis. 2007;194:e43–e51
  25. Deveraj S, Siegel D, Jialal I. Simvastati (40mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol. 2007;100:1397–1399
  26. Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol. 2006;98:66–69
  27. Ganange-Yared MH, Azar RR, Amm-Azar M, Khalife S, Germanos-Haddad M, Neemtallah R, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism. 2005;54:947–951
  28. ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AFH. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidemia. Eur J Clin Invest. 2005;35:558–564
  29. Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J. 2005;26:2664–2672
  30. Watts FH, Barrett PHR, Ji J, Serone AP, Chan DC, Croft KD, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003;52:803–811
  31. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 2003;20:743–745
  32. Altunbas H, Balci MK, Karayalcin U. No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. Endocr Res. 2003;29:265–275
  33. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men. A randomized controlled trial. JAMA. 2002;287:598–605
  34. Chan DC, Watts FG, Barret PHR, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877–883
  35. The Cochrane Collaboration. In:  Higgins JPT,  Green S editor. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. 2008;Available from www.cochrane-handbook.org. Accessed 12/4/2008
  36. Wong SSL, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc. 2006;94:451–455
  37. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–E26
  38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  39. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495
  40. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410
  41. Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Koyama H, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab. 2004;89:1481–1484
  42. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  43. Follman D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45:731–769
  44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  45. Veerkamp MJ, de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Nomogram to diagnose familial combined hyperlipidemia on the bases of results of a 5-year follow-up study. Circulation. 2004;109:2980–2985
  46. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP for the TIMI Study Group. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation. 2004;110(Suppl. III):III-834
  47. Hanefeld M, Marx N, Pfutzner A, Baurecht W, Luuben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity c-reactive protein. The PIOSTAT study. J Am Coll Cardiol. 2007;49:290–297
  48. Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, et al. ACTos NOW for the prevention of diabetes (ACT NOW) study. Diabetologia. 2008;51(Suppl. 1):S1–S588(Abstract)
  49. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia. 2006;49:1881–1892
  50. Mita T, Watada H, Nakayama S, Abe M, Ogihara T, Shimizu T, et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J. 2007;54:441–447
  51. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–970
  52. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol. 2004;19:117–125
  53. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharmacol. 1999;126:1205–1213
  54. Masters BA, Palmoski MJ, Glint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductast inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163–174
  55. Gotzsche PC, Hrobjartsson A, Marie K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA. 2007;298:430–437

PII: S0168-8227(09)00433-1

doi: 10.1016/j.diabres.2009.10.008

Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 98-107 , January 2010

Article Tools

* Image Usage & Resolution